Transplantation of human umbilical mesenchymal stem cells attenuates dextran sulfate sodium-induced colitis in mice

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 1, 2015, Pages 76-86

  Lin, Yan ^a   Lin, Lianjie ^a   Wang, Qiushi ^a   Jin, Yu ^a   Zhang, Ying ^a   Cao, Yong ^a   Zheng, Changqing ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Inflammation; Tight junction; Ulcerative colitis; Umbilical mesenchymal stem cells

Indexed keywords

BETA ACTIN; CLAUDIN 1; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; MYELOPEROXIDASE; OCCLUDIN; PROTEIN ZO1; TIGHT JUNCTION PROTEIN; DEXTRAN SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLON; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DISEASE SEVERITY; DOWN REGULATION; FECES; HEMATOLOGICAL PARAMETERS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INTESTINE MUCOSA PERMEABILITY; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECTUM HEMORRHAGE; UMBILICAL MESENCHYMAL STEM CELL; UPREGULATION; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; COLITIS; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOLOGY; FETUS BLOOD; PATHOLOGY; PROCEDURES; TRANSPLANTATION;

ANIMALS; CELLS, CULTURED; COLITIS; CORD BLOOD STEM CELL TRANSPLANTATION; DEXTRAN SULFATE; FETAL BLOOD; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; MICE, INBRED C57BL;

EID: 84919624982     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12321     Document Type: Article

References (55)

1. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 2002; 20: 495-549.
2. Vagefi PA, Longo WE. Colorectal cancer in patients with inflammatory bowel disease. Clin. Colorectal Cancer 2005; 4: 313-9.
3. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-35.
4. McCracken MD, Carlton WW, Tuite J. Penicillium viridicatum mycotoxicosis in the rat. IV. Attempts to modify the tissue responses. Food Cosmet. Toxicol. 1974; 12: 331-40.
5. Delorme B, Ringe J, Pontikoglou C et al. Specific lineage-priming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity. Stem Cells 2009; 27: 1142-51.
6. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-7.
7. Sacchetti B, Funari A, Michienzi S et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007; 131: 324-36.
8. Troyer DL, Weiss ML. Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells 2008; 26: 591-9.
9. Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C. Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications. Curr. Stem Cell Res. Ther. 2013; 8: 144-55.
10. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 2003; 3: 521-33.
11. Rubin DT, Huo D, Kinnucan JA et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin. Gastroenterol. Hepatol. 2013; 11: 1601-8 e1-4.
12. Rosenberg L, Nanda KS, Zenlea T et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin. Gastroenterol. Hepatol. 2013; 11: 991-6.
13. He XW, He XS, Lian L, Wu XJ, Lan P. Systemic infusion of bone marrow-derived mesenchymal stem cells for treatment of experimental colitis in mice. Dig. Dis. Sci. 2012; 57: 3136-44.
14. Ko IK, Kim BG, Awadallah A et al. Targeting improves MSC treatment of inflammatory bowel disease. Mol. Ther. 2010; 18: 1365-72.
15. Hayashi Y, Tsuji S, Tsujii M et al. Topical implantation of mesenchymal stem cells has beneficial effects on healing of experimental colitis in rats. J. Pharmacol. Exp. Ther. 2008; 326: 523-31.
16. Kim HS, Shin TH, Lee BC et al. Human umbilical cord blood mesenchymal stem cells reduce colitis in mice by activating NOD2 signaling to COX2. Gastroenterology 2013; 145: 1392-403 e1-8.
17. Wexler SA, Donaldson C, Denning-Kendall P, Rice C, Bradley B, Hows JM. Adult bone marrow is a rich source of human mesenchymal 'stem' cells but umbilical cord and mobilized adult blood are not. Br. J. Haematol. 2003; 121: 368-74.
18. Perdikogianni C, Dimitriou H, Stiakaki E, Martimianaki G, Kalmanti M. Could cord blood be a source of mesenchymal stromal cells for clinical use? Cytotherapy 2008; 10: 452-9.
19. Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog. Biophys. Mol. Biol. 2003; 81: 1-44.
20. Kyoko OO, Kono H, Ishimaru K et al. Expressions of tight junction proteins Occludin and Claudin-1 are under the circadian control in the mouse large intestine: implications in intestinal permeability and susceptibility to colitis. PLoS ONE 2014; 9: e98016.
21. Bruewer M, Utech M, Ivanov AI, Hopkins AM, Parkos CA, Nusrat A. Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis-like process. FASEB J. 2005; 19: 923-33.
22. Bruewer M, Luegering A, Kucharzik T et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J. Immunol. 2003; 171: 6164-72.
23. Kucharzik T, Walsh SV, Chen J, Parkos CA, Nusrat A. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am. J. Pathol. 2001; 159: 2001-9.
24. Mees ST, Mennigen R, Spieker T et al. Expression of tight and adherens junction proteins in ulcerative colitis associated colorectal carcinoma: upregulation of claudin-1, claudin-3, claudin-4, and beta-catenin. Int. J. Colorectal Dis. 2009; 24: 361-8.
25. Liang L, Dong C, Chen X et al. Human umbilical cord mesenchymal stem cells ameliorate mice trinitrobenzene sulfonic acid (TNBS)-induced colitis. Cell Transplant. 2011; 20: 1395-408.
26. Oh SY, Cho KA, Kang JL, Kim KH, Woo SY. Comparison of experimental mouse models of inflammatory bowel disease. Int. J. Mol. Med. 2014; 33: 333-40.
27. Liu S, Hou KD, Yuan M et al. Characteristics of mesenchymal stem cells derived from Wharton's jelly of human umbilical cord and for fabrication of non-scaffold tissue-engineered cartilage. J. Biosci. Bioeng. 2014; 117: 229-35.
28. Siegmund B, Rieder F, Albrich S et al. Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J. Pharmacol. Exp. Ther. 2001; 296: 99-105.
29. Patel RB, Prajapati KD, Sonara BM et al. Ameliorative potential of aliskiren in experimental colitis in mice. Eur. J. Pharmacol. 2014; 737: 70-6.
30. Kitajima S, Takuma S, Morimoto M. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp. Anim. 1999; 48: 137-43.
31. Chen M, Xiang Z, Cai J. The anti-apoptotic and neuro-protective effects of human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) on acute optic nerve injury is transient. Brain Res. 2013; 1532: 63-75.
32. Ma S, Liang S, Jiao H et al. Human umbilical cord mesenchymal stem cells inhibit C6 glioma growth via secretion of dickkopf-1 (DKK1). Mol. Cell. Biochem. 2014; 385: 277-86.
33. Anderson JM, Van Itallie CM. Tight junctions and the molecular basis for regulation of paracellular permeability. Am. J. Physiol. 1995; 269: G467-75.
34. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98: 694-702.
35. Zhang Q, Shi S, Liu Y et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J. Immunol. 2009; 183: 7787-98.
36. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 2009; 136: 978-89.
37. Kristjansson G, Venge P, Wanders A, Loof L, Hallgren R. Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut 2004; 53: 1806-12.
38. Hakansson A, Tormo-Badia N, Baridi A et al. Immunological alteration and changes of gut microbiota after dextran sulfate sodium (DSS) administration in mice. Clin. Exp. Med. 2014; 11.
39. Olsen T, Goll R, Cui G et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand. J. Gastroenterol. 2007; 42: 1312-20.
40. Itzkowitz SH. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol. Clin. North Am. 2006; 35: 553-71.
41. Rosillo MA, Sanchez-Hidalgo M, Cardeno A et al. Dietary supplementation of an ellagic acid-enriched pomegranate extract attenuates chronic colonic inflammation in rats. Pharmacol. Res. 2012; 66: 235-42.
42. Bitton A, Dobkin PL, Edwardes MD et al. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut 2008; 57: 1386-92.
43. Clayburgh DR, Musch MW, Leitges M, Fu YX, Turner JR. Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. J. Clin. Investig. 2006; 116: 2682-94.
44. Ma TY. Intestinal epithelial barrier dysfunction in Crohn's disease. Proc. Soc. Exp. Biol. Med. 1997; 214: 318-27.
45. Mankertz J, Schulzke JD. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr. Opin. Gastroenterol. 2007; 23: 379-83.
46. Al-Sadi R, Khatib K, Guo S, Ye D, Youssef M, Ma T. Occludin regulates macromolecule flux across the intestinal epithelial tight junction barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 2011; 300: G1054-64.
47. Fanning AS, Ma TY, Anderson JM. Isolation and functional characterization of the actin binding region in the tight junction protein ZO-1. FASEB J. 2002; 16: 1835-7.
48. Mennigen R, Nolte K, Rijcken E et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2009; 296: G1140-9.
49. Li X, Wang Q, Xu H et al. Somatostatin regulates tight junction proteins expression in colitis mice. Int. J. Clin. Exp. Pathol. 2014; 7: 2153-62.
50. Xia XM, Wang FY, Zhou J, Hu KF, Li SW, Zou BB. CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis. PLoS ONE 2011; 6: e27282.
51. Kinugasa T, Akagi Y, Yoshida T et al. Increased claudin-1 protein expression contributes to tumorigenesis in ulcerative colitis-associated colorectal cancer. Anticancer Res. 2010; 30: 3181-6.
52. Poritz LS, Harris LR 3rd, Kelly AA, Koltun WA. Increase in the tight junction protein claudin-1 in intestinal inflammation. Dig. Dis. Sci. 2011; 56: 2802-9.
53. Youakim A, Ahdieh M. Interferon-gamma decreases barrier function in T84 cells by reducing ZO-1 levels and disrupting apical actin. Am. J. Physiol. 1999; 276: G1279-88.
54. Mankertz J, Tavalali S, Schmitz H et al. Expression from the human occludin promoter is affected by tumor necrosis factor alpha and interferon gamma. J. Cell Sci. 2000; 113(Pt 11): 2085-90.
55. Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am. J. Pathol. 2005; 166: 409-19.